Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cytochrome P450, family 19, subfamily A, polypeptide 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma cruzi | cytochrome P450, putative | cytochrome P450, family 19, subfamily A, polypeptide 1 | 503 aa | 425 aa | 18.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Echinococcus multilocularis | 6 phosphogluconolactonase | 0.0128 | 0.9435 | 0.9653 |
Loa Loa (eye worm) | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 0.9435 |
Leishmania major | glucose-6-phosphate isomerase | 0.0049 | 0.2043 | 0.1317 |
Trypanosoma cruzi | 6-phosphogluconolactonase, putative | 0.0128 | 0.9435 | 1 |
Schistosoma mansoni | glucose-6-phosphate isomerase | 0.0049 | 0.2043 | 0.1317 |
Trichomonas vaginalis | glucose-6-phosphate isomerase, putative | 0.0049 | 0.2043 | 1 |
Entamoeba histolytica | glucose-6-phosphate isomerase, putative | 0.0049 | 0.2043 | 1 |
Mycobacterium leprae | Probable 6-phosphogluconolactonase DevB (6PGL) | 0.0128 | 0.9435 | 1 |
Plasmodium vivax | glucose-6-phosphate isomerase, putative | 0.0049 | 0.2043 | 1 |
Schistosoma mansoni | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Schistosoma mansoni | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Echinococcus multilocularis | n acetylated alpha linked acidic dipeptidase 2 | 0.013 | 0.9701 | 1 |
Plasmodium falciparum | glucose-6-phosphate isomerase | 0.0049 | 0.2043 | 1 |
Brugia malayi | 6-phosphogluconolactonase family protein | 0.0128 | 0.9435 | 1 |
Trypanosoma cruzi | glucose-6-phosphate isomerase, glycosomal, putative | 0.0049 | 0.2043 | 0.1317 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.2043 | 0.2043 |
Toxoplasma gondii | glucose-6-phosphate isomerase GPI | 0.0049 | 0.2043 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0122 | 0.8884 | 0.8884 |
Chlamydia trachomatis | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Treponema pallidum | glucose-6-phosphate 1-dehydrogenase | 0.0128 | 0.9435 | 1 |
Trypanosoma brucei | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Trypanosoma brucei | glucose-6-phosphate isomerase, glycosomal | 0.0049 | 0.2043 | 0.1317 |
Mycobacterium ulcerans | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Trypanosoma cruzi | 6-phosphogluconolactonase, putative | 0.0128 | 0.9435 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0089 | 0.5772 | 0.5772 |
Giardia lamblia | Glucose-6-phosphate isomerase | 0.0049 | 0.2043 | 1 |
Trichomonas vaginalis | glucose-6-phosphate isomerase, putative | 0.0049 | 0.2043 | 1 |
Echinococcus granulosus | 6 phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Trypanosoma cruzi | glucose-6-phosphate isomerase, glycosomal, putative | 0.0049 | 0.2043 | 0.1317 |
Mycobacterium tuberculosis | Probable 6-phosphogluconolactonase DevB (6PGL) | 0.009 | 0.5947 | 1 |
Loa Loa (eye worm) | phosphoglucose isomerase | 0.0049 | 0.2043 | 0.2043 |
Schistosoma mansoni | NAALADASE L peptidase (M28 family) | 0.0085 | 0.5473 | 0.5346 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 0.063 uM | Inhibition of binding to human Placental Cytochrome P450 19A1 | ChEMBL. | 2033599 |
Ki (binding) | = 0.063 uM | Inhibition of binding to human Placental Cytochrome P450 19A1 | ChEMBL. | 2033599 |
Ratio (binding) | = 50700 | Ratio of Kcat to Ki for human placental cytochrome P450 19A1 | ChEMBL. | 2033599 |
Ratio (binding) | = 50700 | Ratio of Kcat to Ki for human placental cytochrome P450 19A1 | ChEMBL. | 2033599 |
T50 (ADMET) | = 3.6 min | Pseudo first-order inactivation rate of the compound calculated by using Kitz-Wilson Plot | ChEMBL. | 2033599 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.